$343.34
+10.52 (+3.16%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where KRYS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 3 observational · 2 with posted results
Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Bridgewater Associates, LP, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, +2 more) · FINRA short interest 4.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 24 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Follow-up ProtocolNCT04917887observationalSerious Adverse Events (AE) | — | Recruiting | — | Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | 50 | 2028-05-25 | in 644 d | 2021-06-08 |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsNCT05970497Percentage of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: KB707 · Drug: Opdualag, KEYTRUDA ®( Pembrolizumab) | Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma | 240 | Jul 2027 | ≤ 345 d | 2025-05-18 |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsNCT06228326To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: KB707 · Drug: Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel | Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC) | 250 | Feb 2027 | ≤ 192 d | 2025-10-24 |
| A Study Assessing KB407 for the Treatment of Cystic FibrosisNCT05504837To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test resultsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: KB407 (Nebulization) | Cystic Fibrosis | 20 | Dec 2026 | ≤ 133 d | 2026-05-07 |
| A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisNCT06999733To evaluate safety and tolerability of KB801 based upon assessment of adverse events (frequency, severity, relatedness).Randomized · Triple-masked · Treatment | Phase 1/2 | Recruiting | Biological: KB801 · Drug: Placebo | Neurotrophic Keratitis | 60 | Dec 2026 | ≤ 133 d | 2026-02-27 |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaNCT07016750To evaluate the safety and tolerability of KB803.Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: KB803 · Drug: Placebo | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | 16 | Dec 2026 | ≤ 133 d | 2026-03-12 |
| A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey DiseaseNCT07717346To evaluate the safety and tolerability of KB111Open-label · Treatment | Early Phase 1 | Recruiting | Biological: KB111 | Hailey Hailey Disease, Skin Diseases, Lesion Skin | 7 | Nov 2026 | ≤ 102 d | 2026-07-21 |
| A Study of KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyNCT06049082To evaluate safety and tolerability of KB408 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in vital signs, ECG, spirometry, and clinical laboratory test resultsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: KB408 (Nebulization) | Alpha 1-Antitrypsin Deficiency | 15 | Dec 2025 | — | 2025-07-22 |
| A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)NCT06563414observationalCorneal abrasion frequency | — | Recruiting | — | Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans | 40 | Dec 2025 | — | 2025-07-02 |
| A Study Assessing KB304 for the Treatment of Wrinkles in WomenNCT06724900Safety and tolerability of KB304 versus placebo administered by intradermal injectionRandomized · Triple-masked · Treatment | Phase 1/2 | Active, not recruiting | Biological: KB304 · Drug: 0.9% Normal Saline (NS) | Wrinkles in Decolletage, Pigmentation, Décolleté Wrinkles | 19 | Jul 2025 | — | 2025-05-13 |
| A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin DepressionsNCT04540900Assessment of the safety profile of KB301 by recording adverse events using MedDRA System Organ Class and Preferred Term and collection of other clinical study procedures.Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: KB301 · Other: Placebo | Skin Roughness, Wrinkle, Fine Lines, Skin Thickness | 85 | 2024-10-16actual | — | 2025-05-13 |
| A Study of Inhaled KB407 for the Treatment of Cystic FibrosisNCT05095246To evaluate the safety and tolerability of KB407 in subjects with Cystic Fibrosis through adverse events as assessed by NCI-CTCAE v5.0Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Pandemic, logistical, and recruitment challenges | Biological: KB407 (Nebulization) | Cystic Fibrosis | 0 | 2024-07-01 | — | 2023-08-14 |
| Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)NCT05735158Composite Investigator's Global Assessment (IGA) Responder (Comparison of proportion of responder KB105 target areas to responder placebo target areas)Randomized · Triple-masked · Treatment | Phase 2 | Unknown status | Biological: KB105 · Other: Placebo | Autosomal Recessive Ichthyosis | 15 | Mar 2024 | — | 2023-02-23 |
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaNCT04917874To record safety outcomes of participants while on B-VEC.Open-label · Treatment | Phase 3 | Completed | Biological: Open Label Topical Beremagene Geperpavec (B-VEC) | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | 47 | 2023-07-31actual | — | 2024-04-09 |
| Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)NCT04047732Safety and tolerabilityOpen-label · Treatment | Phase 1/2 | Unknown status | Biological: KB105 | TGM-1 Related Autosomal Recessive Congenital Ichthyosis | 6 | Oct 2022 | — | 2021-09-13 |
| Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBNCT04491604results2023-02-17Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Topical Beremagene Geperpavec · Other: Placebo | Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | 31 | 2021-10-29actual | — | 2023-02-17 |
| The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)NCT04214002observationalChange in wound surface area | — | Withdrawnsponsor's stated reason: Due to the COVID-19 Pandemic, the study was withdrawn. | — | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | 0 | 2020-02-24actual | — | 2021-09-17 |
| A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB PatientsNCT03536143results2023-01-31Number of Subjects Reported at Least One Adverse Event, Safety PopulationRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Topical beremagene geperpavec, Placebo gel | Dystrophic Epidermolysis Bullosa | 12 | 2019-11-01actual | — | 2023-01-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19